{{chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 458266470 | ImageFile = Pinacidil structure.svg | ImageClass = skin-invert-image | ImageSize = | IUPACName = ''N''-cyano-''N'''-pyridin-4-yl-''N<nowiki>''</nowiki>''-(1,2,2-trimethylpropyl)guanidine | OtherNames = |Section1={{Chembox Identifiers | UNII_Ref = {{fdacite|correct|FDA}} | UNII = BB4UGO5K0D | UNII_Comment = (anhydrous) | UNII1_Ref = {{fdacite|correct|FDA}} | UNII1 = 7B0ZZH8P2W | UNII1_Comment = (monohydrate) | CASNo1_Ref = {{cascite|correct|CAS}} | CASNo1= 85371-64-8 | CASNo1_Comment= (monohydrate) | CASNo_Ref = {{cascite|correct|CAS}} | CASNo= 60560-33-0 | CASNo_Comment= (anhydrous) | PubChem=4826 | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 1159 | ChEMBL2_Ref = {{ebicite|changed|EBI}} | ChEMBL2 = 1200338 | IUPHAR_ligand = 2412 | SMILES=CC(C(C)(C)C)N=C(NC#N)NC1=CC=NC=C1 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = 4660 | InChI = 1/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18) | InChIKey = IVVNZDGDKPTYHK-UHFFFAOYAY | StdInChI_Ref = {{stdinchicite|changed|chemspider}} | StdInChI = 1S/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18) | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | StdInChIKey = IVVNZDGDKPTYHK-UHFFFAOYSA-N }} |Section2={{Chembox Properties | Formula=C<sub>13</sub>H<sub>19</sub>N<sub>5</sub> | MolarMass=245.32346 | Appearance= | Density= | MeltingPt= | BoilingPt= | Solubility= }} |Section6={{Chembox Pharmacology | ATCCode_prefix = C02 | ATCCode_suffix = DG01 }} |Section7={{Chembox Hazards | MainHazards= | FlashPt= | AutoignitionPt = }} }}
'''Pinacidil''' is a cyanoguanidine drug that opens ATP-sensitive potassium channels producing peripheral vasodilatation of arterioles.<ref name="pmid7473155">{{cite journal | vauthors = Gollasch M, Bychkov R, Ried C, Behrendt F, Scholze S, Luft FC, Haller H | title = Pinacidil relaxes porcine and human coronary arteries by activating ATP-dependent potassium channels in smooth muscle cells | journal = J. Pharmacol. Exp. Ther. | volume = 275 | issue = 2 | pages = 681–92 | year = 1995 | pmid = 7473155 | url = http://jpet.aspetjournals.org/cgi/content/abstract/275/2/681 | archive-date = 2008-02-09 | access-date = 2008-03-08 | archive-url = https://web.archive.org/web/20080209194454/http://jpet.aspetjournals.org/cgi/content/abstract/275/2/681 | url-status = dead }}</ref> It reduces blood pressure and peripheral resistance and produces fluid retention.<ref name="isbn0-85369-342-0">{{cite book | author1 = Reynolds, James Blair | author2 = Martindale, William L. | title = The extra pharmacopoeia | publisher = Royal Pharmaceutical Society | location = London | year = 1996 | edition = 31st | pages = [https://archive.org/details/martindaleextrap00will/page/2739 2739 pages] | isbn = 0-85369-342-0 | url-access = registration | url = https://archive.org/details/martindaleextrap00will/page/2739 }}</ref>
Pinacidil has been associated with development of hypertrichosis in 2 to 13% of patients.<ref name="RossiCantisaniMelis2012">{{cite journal | vauthors = Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S | title = Minoxidil use in dermatology, side effects and recent patents | journal = Recent Pat Inflamm Allergy Drug Discov | volume = 6 | issue = 2 | pages = 130–136 | date = May 2012 | pmid = 22409453 | doi = 10.2174/187221312800166859 | url = | quote = Other potassium channel openers, like diazoxide [39, 40] and pinacidil [41] can cause hypertrichosis in humans as well as minoxidil. In balding macaques minoxidil, cromakalin and P-1075 (a pinacidil analogue) stimulate hair growth in about 20 weeks of topical treatment, whereas a fourth potassium channel opener, called RP49356, is not effective [42].}}</ref><ref name="BuhlConradWaldon1993">{{cite journal | vauthors = Buhl AE, Conrad SJ, Waldon DJ, Brunden MN | title = Potassium channel conductance as a control mechanism in hair follicles | journal = J Invest Dermatol | volume = 101 | issue = 1 Suppl | pages = 148S–152S | date = July 1993 | pmid = 8326149 | doi = 10.1111/1523-1747.ep12363290 | url = | quote = The evidence that [potassium channel openers (PCOs)] are active on hair growth is correlative. In humans three PCOs have been reported to affect hair growth. Minoxidil was reported to induce hypertrichosis during early clinical trials as an antihypertensive [12]. These side effects were characterized by increasingly visual facial hair, thickening of eyebrows, and diffuse hair growth across the upper back and limbs. Systemic minoxidil induced hypertrichosis in 80–100% of adults [13]. Clinical trials using topical minoxidil demonstrate increased scalp hair in about 39% of treated balding men. Oral diazoxide causes hypertrichosis in most hypoglycemic children and about 1% of adults, and induces some scalp hair in 25% of the balding patients [13–15]. Systemic pinacidil induces hypertrichosis in 2–13% of patients [13]. We are not aware of any topical hair growth trials using pinacidil.}}</ref>
==Synthesis== [[File:Pinacidil synthesis.svg|thumb|center|500px|[https://pharmaceutical-substances.thieme.com/ps/search-results?docUri=KD-16-0107 Thieme] Synthesis:<ref>Petersen, Hans Joergen; Nielsen, C. Kaergaard; Arrigoni-Martelli, E. (1978). "Synthesis and hypotensive activity of N-alkyl-N-cyano-N'-pyridylguanidines". Journal of Medicinal Chemistry 21 (8): 773–781. doi:10.1021/jm00206a011.</ref><ref>Hansen, E. T.; Petersen, H. J. (2006). "Synthesis ofN-Alkyl-N'-cyano-N″-4-pyridylguanidines from 4-Pyridyldithiocarbamic AcidviaN-Alkyl-N′-4-Pyridylthioureas, orvia4-Pyridylcyaniminothiocarbamic Acid". Synthetic Communications. 14 (13): 1275–1283. doi:10.1080/00397918408076809.</ref><ref>Zhang, Hao; Liu, Rui-Quan; Liu, Ke-Chang; Li, Qi-Bo; Li, Qing-Yang; Liu, Shang-Zhong (2014). "A One-Pot Approach to Pyridyl Isothiocyanates from Amines". Molecules 19(9): 13631–13642. doi:10.3390/molecules190913631.</ref> Patents:<ref>Hans J. Petersen, USRE31244E (1983 to Leo Pharma AS).</ref><ref>Hans Jorgen Petersen, {{US patent|4057636}} (1977 to Leo Pharma AS).</ref>]]
Condensation of 4-isothiocyanotopyridine [76105-84-5] ('''1''') and 3,3-dimethyl-2-butanamine [3850-30-4] ('''2''') gives thiourea [67027-06-9] ('''3'''). Treatment of that intermediate with a mixture of triphenylphosphine, carbon tetrachloride, and triethylamine leads to the unsymmetrical carbodiimide, [https://pubchem.ncbi.nlm.nih.gov/compound/20501933 CID:20501933] ('''4''''). Addition of cyanamid affords pinacidil ('''5'''). ==References== {{Reflist}}
==External links== * {{MeshName|Pinacidil}}
{{Ion channel modulators}}
Category:4-Pyridyl compounds Category:Cyanamides Category:KATP channel openers
{{Cardiovascular-drug-stub}}